WASHINGTON — Johns Hopkins surgeon Marty Makary has criticized – sometimes with harsh language – the Food and Drug Administration that President-elect Trump has tapped him to lead.
His remarks have been particularly acute since the Covid-19 pandemic began. Among his complaints: That the agency was not moving quickly enough to authorize innovative products to prevent and treat Covid-19. That the FDA doesn’t place enough emphasis on recommendations from its expert advisory panels. Further, he’s not a fan of remote work and wants to see more active monitoring of adverse events caused by vaccines.
To get a sense of what changes he might make to the agency if he’s confirmed by the Senate in 2025, STAT has rounded up the issues about which Makary has publicly disagreed with the FDA.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in